

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

THIOSEMICARBAZONES AS INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE (TDO), AN EMERGING TARGET FOR CANCER TREATMENT

Dolusic, Eduard; Modaffari, Sara; Larrieu, Pierre; Vancraeynest, Christelle; Pilotte, Luc; Colau, Didier; Stroobant, Vincent; Van den Eynde, Benoît; Wouters, Johan; Masereel, Bernard; Frédérick, Raphaël

Publication date:
2011

Document Version
Early version, also known as pre-print

[Link to publication](#)

Citation for published version (HARVARD):

Dolusic, E, Modaffari, S, Larrieu, P, Vancraeynest, C, Pilotte, L, Colau, D, Stroobant, V, Van den Eynde, B, Wouters, J, Masereel, B & Frédérick, R 2011, 'THIOSEMICARBAZONES AS INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE (TDO), AN EMERGING TARGET FOR CANCER TREATMENT', Annual One-Day Meeting on Medicinal Chemistry of SRC & KVCV (Medchem 2011), Gand, Belgium, 25/11/11 pp. Book of Abstracts, Annual One-Day Meeting on Medicinal Chemistry of SRC & KVCV (MedChem 2011), Ghent, 25 November 2011, p. 21.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

THIOSEMICARBAZONES AS INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE (TDO), AN EMERGING TARGET FOR CANCER TREATMENT

Eduard Dolušić (a), Sara Modaffari (a), Pierre Larrieu (b), Christelle Vancraeynest (a), Luc Pilotte (b), Didier Colau (b), Vincent Stroobant (b), Benoît Van den Eynde (b), Johan Wouters (a), Bernard Masereel (a), Raphaël Frédérick (a)

(a) *Namur Drug Design and Discovery Center (ND3C), University of Namur (FUNDP), 61 Rue de Bruxelles, B-5000 Namur, Belgium;* (b) *Ludwig Institute for Cancer Research (LICR), Université Catholique de Louvain (UCL), 74 Avenue Hippocrate, B-1200 Brussels, Belgium*

edolusic@fundp.ac.be

Thiosemicarbazones have received a great deal of attention due to their antineoplastic, antibacterial, antiviral, and antifungal activity.¹ Their biological activity has been attributed to metal chelating properties in general² and to the inhibitory activity on ribonucleotide reductase in particular.³ Compounds of this class, such as marboran and triapine, are already used in medical practice.

Indoleamine 2,3-dioxygenase (IDO) is an extrahepatic heme dioxygenase catalysing tryptophan oxidation in the so-called kynurenine pathway of this amino acid catabolism. IDO is involved in tumoral immune resistance: various human tumours express the enzyme constitutively⁴ and the development and synthesis of IDO inhibitors has been an active area of research in the recent years.⁵ A structurally unrelated hepatic enzyme catalysing the same reaction, tryptophan 2,3-dioxygenase (TDO), has lately also been linked to cancer immunopathology.⁶ Our group very recently described a series of ethenyl indole-based TDO inhibitors yielding **LM 10**, a potent (IC_{50} = 2 μ M in a cellular test), selective, orally bioavailable compound which, furthermore, shows anti-cancer activity in preclinical *in vivo* models in mice.⁷

In this work, the synthesis of a small library of aromatic thiosemicarbazones as well as their evaluation and SAR as TDO inhibitors is described. The best compound (**ED 135**) is roughly equipotent to **LM 10** in the cellular test. A new pharmacological profile for aromatic thiosemicarbazones with a potential in an emerging way of cancer treatment is thus demonstrated.⁸

References

- 1) Beraldo, H., Gambino, D., 2004, *Mini-Rev. Med. Chem.* 4, 31–39; Duffy, K.J., et al, 2002, *J. Med. Chem.* 45, 3573.
- 2) Yu, Y., et al, 2009, *J. Med. Chem.* 52, 5271.
- 3) Sartorelli, A.C., et al, 1967, *Cancer Res.* 27, 1614; Sartorelli, A.C., et al, 1971, *Biochem. Pharmacol.* 20, 3119 ; French, F.A., et al, 1970, *J. Med. Chem.* 13, 1117; Klayman, D.L., et al, 1983, *J. Med. Chem.*, 26, 39; Demertzi, D.K., et al, 2001, *J. Inorg. Biochem.* 86, 555; Quiroga, A.G., et al, 1988, *J. Med. Chem.* 41, 1399.
- 4) Uyttenhove, C., et al, 2003, *Nat. Med.* 9, 1269.
- 5) Our contributions to the field: Röhrig, U. F., et al, 2010, *J. Med. Chem.* 53, 1172; Dolušić, E., et al, 2011, *Bioorg. Med. Chem.* 19, 1550; Dolušić, E., et al, 2011, *Eur. J. Med. Chem.* 46, 3058.
- 6) Van den Eynde, B., et al, 2010; WO2010008427; Opitz, C. A., et al, 2011, *Nature* 478, 197.
- 7) Dolušić, E., et al, 2011, *J. Med. Chem.* 54, 5320.
- 8) This work was supported by FNRS-Télévie (7.4.543.07).